Staar Surgical Announces Agreement in US with IQ Laser Vision

Staar Surgical announced a strategic agreement with IQ Laser Vision, which has locations across California and Texas.

IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D. IQ Laser Vision said it intends to nearly double its volume in EVO ICLs over the course of the next 12 months. To support the transition and ramp up, Staar Surgical and IQ Laser Vision will collaborate on marketing, education, practice development and clinical support activities to further elevate awareness of EVO ICL and increase the availability of the lenses to all qualified patients across the IQ Laser Vision family of practices, which includes Scott Hyver Visioncare, Ellis Eye, and Mattioli Vision Professionals.

“While studies show that refractive vision correction may be safer than long-term use of contact lenses, patients have been shying away from corneal-based laser vision correction (such as LASIK) due to a variety of factors. I believe EVO ICL is a way to re-invigorate the refractive surgery category as a whole," Robert T. Lin, MD, founder and surgeon, IQ Laser Vision, said in a Staar news release. "With surgeons across Europe and Asia using EVO ICL across the diopter range, and many offering ICL as the first-line treatment, it’s clear to me that we need to get the word out in the U.S. I am grateful to Staar for recognizing this immense need, and working with us as we help patients achieve their dream of visual freedom.”

"Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the US thus far," Tom Frinzi, Chair of the Board and CEO of STAAR Surgical, said in the news release. "Dr. Lin is a renowned leader and pioneer in refractive eye surgery having performed over 70,000 refractive procedures and is one of the most experienced ICL surgeons in North America, having implanted over 1,000 ICLs over the past 12 months. Dr. Lin’s deep and expansive expertise across refractive surgery makes his decision to offer EVO ICL as a primary option now all the more meaningful.”